Standard Contracts
EXCLUSIVE LICENSE AGREEMENT by and between Passage Bio, Inc. and Gemma Biotherapeutics, INC. July 31, 2024Exclusive License Agreement • November 13th, 2024 • Passage BIO, Inc. • Biological products, (no disgnostic substances) • Pennsylvania
This Exclusive License Agreement (this “Agreement”) is entered into as of July 31, 2024 (the “Effective Date”), by and between Passage Bio, Inc., a corporation organized under the laws of Delaware (“Passage”), with offices at 2005 Market St., 39th Floor, Philadelphia, PA 19103, and Gemma Biotherapeutics, Inc., a Delaware corporation (“Gemma”), with offices at 1831 Delancey Place, Philadelphia, PA 19103. Passage and Gemma may be referred to in this Agreement individually as a “Party” or collectively as the “Parties.”
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT PASSAGE BIO, INC. TREATS AS PRIVATE OR CONFIDENTIAL. SECOND AMENDED AND RESTATED RESEARCH, COLLABORATION &...Research, Collaboration & License Agreement • November 13th, 2024 • Passage BIO, Inc. • Biological products, (no disgnostic substances) • Pennsylvania
This Second Amended and Restated Research, Collaboration & License Agreement (this “Agreement”) is effective as of July 31, 2024 (the “Second Restatement Date”) by and between The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation (“Penn”), and Passage Bio, Inc., a corporation organized under the laws of the state of Delaware (“Licensee”). Penn and Licensee may be referred to herein as a “Party” or, collectively, as “Parties”.
TRANSITION SERVICES AGREEMENTTransition Services Agreement • November 13th, 2024 • Passage BIO, Inc. • Biological products, (no disgnostic substances) • Pennsylvania
This Transition Services Agreement (this “Agreement”) is entered into as of July 31, 2024 (the “Effective Date”), by and between Passage Bio, Inc., a corporation organized under the laws of Delaware (“Passage”) with offices at 2005 Market St, 39th Floor, Philadelphia, PA 19103, and Gemma Biotherapeutics, Inc., a Delaware corporation (“Gemma”) with offices at 1831 Delancey Place, Philadelphia, PA 19103. Passage and Gemma may be referred to in this Agreement individually as a “Party” or collectively as the “Parties.” Capitalized terms used but not defined herein will have the meanings ascribed to them in the applicable License Agreement (as defined below).
RESEARCH, COLLABORATION & LICENSE AGREEMENT DATED AS OF July 31, 2024 BY AND BETWEEN GEMMA BIOTHERAPEUTICS, INC. AND PASSAGE BIO, INC.Research, Collaboration & License Agreement • November 13th, 2024 • Passage BIO, Inc. • Biological products, (no disgnostic substances) • Pennsylvania
This Research, Collaboration & License Agreement (this “Agreement”) is effective as of July 31, 2024 (“Effective Date”) by and between Gemma Biotherapeutics, Inc., a corporation organized under the laws of the state of Delaware (“Gemma”), and Passage Bio, Inc., a corporation organized under the laws of the state of Delaware (“Passage”). Gemma and Passage may be referred to herein as a “Party” or, collectively, as “Parties”.
